Stock IOVA IOVANCE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
8.885 USD -1.28% Intraday chart for Iovance Biotherapeutics, Inc. -11.24% +9.29%
Jun. 01 Transcript : Iovance Biotherapeutics, Inc. - Special Call
May. 13 Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Iovance Biotherapeutics, Inc. - Special Call
Iovance Biotherapeutics : Corporate Presentation
PU
Iovance Biotherapeutics : IOV COM 202 Cohort 1A ASCO 2024 Oral Presentation
PU
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
AQ
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
AQ
Iovance Biotherapeutics : 2022 Annual Report
PU
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained
MT
Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating
MT
Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says
MT
Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates
MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours
MT
Transcript : Iovance Biotherapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Iovance Biotherapeutics: Q1 Earnings Snapshot
AQ
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000
MT
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
AQ
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IOVA Stock
  4. News Iovance Biotherapeutics, Inc.